Edwards Lifesciences Stock Gains 39% In Q2, Aided By Sapien Valve Sales
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' report of faster-than-expected European market adoption of its Sapien transcatheter aortic heart valves helped propel a 39% leap in the firm's stock price in the second quarter to $62.04